SECENDS - BSX

2025

Q4 4 filings

Nov 19

2026 Annual Bonus Plan and Performance Share Programs Adopted

Awards to certain executive officers under both programs are subject to discretionary recoupment policy

8-K View →

Nov 3

Q3 2025 Results

Financial data not clearly visible in provided XBRL format

10-Q View →

Oct 23

Director John E. Sununu Not Standing for Re-election

John E. Sununu departing 2026 Annual Meeting after 17 years

8-K View →

Oct 22

Q3 Earnings

Q3 2025 financial results for quarter ended Sept 30, 2025

8-K View →

Q3 3 filings

Sep 4

EVP Peripheral Interventions Retired

Jeffrey B. Mirviss retiring Dec 1, 2025, $705K base salary

8-K View →

Aug 1

Q2 2025 Results

Revenue and EPS data not clearly extractable from XBRL format provided

10-Q View →

Jul 23

Q2 Earnings

Q2 2025 financial results announced

8-K View →

Q2 5 filings

May 28

Discontinued ACURATE Valve Systems

Worldwide discontinuation of ACURATE neo2 and Prime Aortic Valve Systems

8-K View →

May 6

2025 Annual Shareholder Meeting Results

All 10 directors elected, say-on-pay approved, simple majority vote proposal passed

8-K View →

May 1

Q1 2025 Results

Unable to extract revenue and EPS - filing contains only XBRL metadata without actual financial values

10-Q View →

Apr 23

Q1 2025 Earnings

Q1 2025 financial results announced

8-K View →

Apr 23

CFO Transition

Daniel Brennan retiring as CFO, Jonathan Monson promoted effective June 30

8-K View →

Q1 6 filings

Mar 19

2025 Proxy Statement

CEO comp: Not disclosed, Say-on-pay: Advisory vote scheduled

DEF 14A View →

Feb 26

Euro Debt Offering

€1.5B notes issued (€850M 2031 at 3.0%, €650M 2034 at 3.25%)

8-K View →

Feb 18

FY2024 Results

Unable to extract specific revenue and EPS figures from provided XBRL data

📌 Multiple strategic acquisitions completed including Silk Road Medical (Sep 2024), Axonics (Nov 2024), and Intera Oncology (Nov 2024)

10-K View →

Feb 12

Director Not Standing for Re-election

Charles J. Dockendorff stepping down after 10 years

8-K View →

Feb 5

Q4 2024 Earnings

Q4 and full year 2024 financial results announced

8-K View →

Jan 16

LOTUS Edge Valve Settlement

Court preliminary approval Jan 8, final hearing Mar 25

8-K View →

2024

Q4 5 filings

Nov 22

2025 Compensation Plans Approved

Annual bonus plan with 0-225% payout range, performance shares with 0-200% range

8-K View →

Nov 15

Acquired Axonics Inc

$3.7B equity value, $71/share cash

8-K View →

Nov 7

Resumed AVANT GUARD Clinical Trial

Trial studying drug-naïve patients with persistent atrial fibrillation resumed after data monitoring committee assessment

8-K View →

Nov 1

Q3 2024 Results

Financial figures not extractable from XBRL metadata provided

10-Q View →

Oct 23

Q3 Earnings

Q3 2024 financial results for quarter ended Sept 30

8-K View →

Q3 3 filings

Aug 1

Q2 2024 Results

Unable to extract revenue and EPS figures from provided XBRL taxonomy data

10-Q View →

Jul 30

New Director Appointed

David C. Habiger appointed to Board, ~$256K prorated compensation

8-K View →

Jul 24

Q2 2024 Earnings

Q2 2024 financial results announced

8-K View →

Q2 5 filings

May 10

New Director Appointed & Credit Line Extended

Dr. Cheryl Pegus joins board, $2.75B credit facility extended to 2029

8-K View →

May 6

Annual Shareholder Meeting

9 directors elected, bylaws amended for proxy rules

8-K View →

May 1

Q1 2024 Results

Unable to extract revenue and EPS figures from provided XBRL data

10-Q View →

Apr 24

Q1 Earnings

Q1 2024 financial results for quarter ended March 31, 2024

8-K View →

Apr 4

Current Report

8-K View →

Q1 6 filings

Feb 27

Current Report

8-K View →

Feb 20

Annual Report

10-K View →

Jan 31

Current Report

8-K View →

Jan 31

Current Report

8-K View →

Jan 8

Current Report

8-K View →

Jan 8

Current Report

8-K View →